Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 37.87

+33.8%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (157)	3/20/2008 11:13:11 AM
From: scaram(o)uche	of 566

Yup, same molecule! Thanks, George. I remembered the old HCV program, but didn't believe that six years could pass before such a vague (molecular target unknown) description would surface. >> Rigel discovered and retains all rights to R803, a small molecule candidate for hepatitis C that could enter the clinic by year-end 2003 << This molecule was the only reason that I was interested in Rigel, "back when". So....... Gilda Radnering...... never mind.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next